Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. ÌýYou can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
WELCOME BACK
or
Phase 3 study of anti-CCR4 monoclonal antibody mogamualizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL)
À¶Ý®ÊÓƵ
Phase 3 study of anti-CCR4 monoclonal antibody mogamualizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL) Kim, Y. H., Bagot, M., Eradat, H., Carson, K., Greer, J. P., Kim, E. J., Kuzel, T., Hughey, L. C., Pollgone, B., Lansigan, F., Zinrani, P., Grandinetti, L. M., Porcu, P., Shustov, A. R., Korman, N., Halwani, A., Sokol, L., Duvic, M., Kyowa Hakko Kirin Pharma Author's AMER SOC CLINICAL ONCOLOGY. 2014View details for
View details for